Filip Roos - Brisbane CA Ralph Schwall - Pacifica CA
Assignee:
Genentech, Inc, - So. San Francisco CA
International Classification:
A61K 3818 C07K 14475 C12N 1512 C07H 2104
US Classification:
514 12
Abstract:
The present invention provides methods for preventing occurrence or progression of liver damage using hepatocyte growth factor. In the methods, a preventatively effective amount of the hepatocyte growth factor is administered to the patient. The hepatocyte growth factor can be administered, for instance, prior to administering a hepatotoxic therapy to the patient. The hepatocyte growth factor can further be administered with activin or transforming growth factor-beta to prevent liver damage. Compositions comprising hepatocyte growth factor and activin antagonist or transforming growth factor-beta antagonist are also provided by the invention.
Filip Roos - Brisbane CA Ralph Schwall - Pacifica CA
Assignee:
Genentech, Inc. - So. San Francisco CA
International Classification:
C07K 14435 C12P 2108 A61K 3900 A61K 3816
US Classification:
5303873
Abstract:
The present invention provides methods for preventing occurrence or progression of liver damage using hepatocyte growth factor. In the methods, a preventatively effective amount of the hepatocyte growth factor is administered to the patient. The hepatocyte growth factor can be administered, for instance, prior to administering a hepatotoxic therapy to the patient. The hepatocyte growth factor can further be administered with activin or transforming growth factor-beta to prevent liver damage. Compositions comprising hepatocyte growth factor and activin antagonist or transforming growth factor-beta antagonist are also provided by the invention.